Lars Gullestad

List of Publications by Citations

Source: https://exaly.com/author-pdf/5235283/lars-gullestad-publications-by-citations.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
8,528
citations

44
h-index

87
g-index

221
ext. papers

5.4
avg, IF

L-index

#	Paper	IF	Citations
210	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , 2007 , 357, 2248-61	59.2	1098
209	Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. <i>Circulation</i> , 1999 , 100, 614-20	16.7	451
208	Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1999 , 83, 376-82	3	390
207	Elevated circulating levels of C-C chemokines in patients with congestive heart failure. <i>Circulation</i> , 1998 , 97, 1136-43	16.7	293
206	Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. <i>Circulation</i> , 2001 , 103, 220-5	16.7	263
205	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 119-29	12.3	248
204	Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1057-1065	40	232
203	Inflammatory cytokines in heart failure: mediators and markers. Cardiology, 2012, 122, 23-35	1.6	220
202	Systemic inflammation in heart failurethe whys and wherefores. <i>Heart Failure Reviews</i> , 2006 , 11, 83-9	2 5	208
201	Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 2061-7	15.1	193
200	Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. <i>Circulation</i> , 2005 , 111, 2461-8	16.7	186
199	Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. <i>European Heart Journal</i> , 2016 , 37, 2406-13	9.5	172
198	Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. <i>Circulation: Heart Failure</i> , 2013 , 6, 219-26	7.6	153
197	Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2006 , 26, 857-63	9.4	153
196	Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1970-6	15.1	148
195	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. <i>Circulation</i> , 2009 , 120, 2188-96	16.7	138
194	Elevated levels of activin A in heart failure: potential role in myocardial remodeling. <i>Circulation</i> , 2004 , 109, 1379-85	16.7	126

(2001-2003)

193	Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. <i>Cardiovascular Research</i> , 2003 , 60, 141-6	9.9	119
192	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2012 , 33, 2290-6	9.5	110
191	Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. <i>Transplantation</i> , 2010 , 89, 864-72	1.8	106
190	Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. <i>American Journal of Cardiology</i> , 2005 , 95, 17C-23C; discussion 38C-40C	3	93
189	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 289-97	7.9	84
188	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failuremodulatory effect of intravenous immunoglobulin. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 187-93	15.1	82
187	Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , 16, 217-	2 ⁴ .1	75
186	The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>American Heart Journal</i> , 2012 , 164, 878-83	4.9	74
185	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2309-2320	15.1	73
184	Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. <i>Cardiovascular Research</i> , 2002 , 54, 175-82	9.9	72
183	Inflammatory cytokines as biomarkers in heart failure. Clinica Chimica Acta, 2015, 443, 71-7	6.2	68
182	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	12.3	65
181	Galectin-3 in heart failure: high levels are associated with all-cause mortality. <i>International Journal of Cardiology</i> , 2011 , 150, 361-4	3.2	65
180	Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. <i>Circulation</i> , 2005 , 112, 3408-14	16.7	65
179	Effect of everolimus introduction on cardiac allograft vasculopathyresults of a randomized, multicenter trial. <i>Transplantation</i> , 2011 , 92, 235-43	1.8	63
178	Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. <i>American Journal of Cardiology</i> , 2001 , 87, 815-8, A9	3	63
177	Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 45, 261-9	5.8	60
176	Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. <i>Circulation</i> , 2001 , 104, 1494-500	16.7	59

175	Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017 , 23, 666-671	3.3	53
174	Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. <i>Transplantation</i> , 2010 , 90, 1581	-9 ^{1.8}	53
173	Effect of metoprolol on cytokine levels in chronic heart failurea substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). <i>American Heart Journal</i> , 2001 , 141, 418-21	4.9	51
172	Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. <i>Circulation: Heart Failure</i> , 2011 , 4, 145-52	7.6	50
171	Exercise after heart transplantation: An overview. World Journal of Transplantation, 2013, 3, 78-90	2.3	49
170	Depressive symptoms and all-cause mortality after heart transplantation. <i>Transplantation</i> , 2007 , 84, 97	'-1:08	47
169	Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. <i>European Journal of Heart Failure</i> , 2014 , 16, 68-75	12.3	46
168	Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1845-1855	15.1	46
167	Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. <i>Transplantation</i> , 2007 , 84, 149-54	1.8	44
166	Effect of thalidomide in patients with chronic heart failure. <i>American Heart Journal</i> , 2002 , 144, 847-50	4.9	42
165	Effect of high-intensity interval training on progression of cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 1073-80	5.8	41
164	Disturbed carnitine regulation in chronic heart failureincreased plasma levels of palmitoyl-carnitine are associated with poor prognosis. <i>International Journal of Cardiology</i> , 2013 , 167, 1892-9	3.2	41
163	Peak oxygen uptake and self-reported physical health are strong predictors of long-term survival after heart transplantation. <i>Clinical Transplantation</i> , 2016 , 30, 161-9	3.8	39
162	Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 641-7	5.8	38
161	Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. <i>Current Heart Failure Reports</i> , 2014 , 11, 146-55	2.8	37
160	Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Circulation: Heart Failure</i> , 2013 , 6, 91-8	7.6	37
159	CXCR4 blockade induces atherosclerosis by affecting neutrophil function. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 74, 44-52	5.8	36
158	One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 181-91	3.9	35

157	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 700-710	6 9.5	35
156	Wnt5a is elevated in heart failure and affects cardiac fibroblast function. <i>Journal of Molecular Medicine</i> , 2017 , 95, 767-777	5.5	34
155	Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bfum Cardiovascular Diabetes (ABCD) cohort study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 126	8.7	34
154	Cytokines as new treatment targets in chronic heart failure. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 271-277		34
153	Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. <i>Heart</i> , 2017 , 103, 1521-1527	5.1	33
152	Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. <i>Circulation: Heart Failure</i> , 2009 , 2, 624-32	7.6	32
151	Agents targeting inflammation in heart failure. Expert Opinion on Investigational Drugs, 2005, 14, 557-66	5.9	31
150	Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia. <i>Circulation</i> , 2019 , 139, 2198-2211	16.7	28
149	Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). <i>Open Heart</i> , 2019 , 6, e001108	3	28
148	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Failure Reviews, 2018 , 23, 303-323	5	27
147	Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart. <i>Life Sciences</i> , 2014 , 97, 145-54	6.8	26
146	The role of intravenous immunoglobulin in the treatment of chronic heart failure. <i>International Journal of Cardiology</i> , 2006 , 112, 40-5	3.2	26
145	Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients. <i>American Heart Journal</i> , 2004 , 147, 49-54	4.9	26
144	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. <i>Transplant International</i> , 2016 , 29, 819-29	3	26
143	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 268-277	12.3	25
142	Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial. <i>ESC Heart Failure</i> , 2018 , 5, 977-984	3.7	25
141	NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture. <i>Cell Reports</i> , 2017 , 18, 82-92	10.6	24
140	Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. <i>International Journal of Cardiology</i> , 2015 , 179, 378-84	3.2	24

139	Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 187-97	7.9	24
138	Prognostic Value of Left Ventricular Deformation Parameters in Patients with Severe Aortic Stenosis: A Pilot Study of the Usefulness of Strain Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 727-735.e1	5.8	23
137	The role of cardiac rehabilitation in secondary prevention after coronary events. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1360-1368	3.9	22
136	Long-term effects of high-intensity interval training in heart transplant recipients: A 5-year follow-up study of a randomized controlled trial. <i>Clinical Transplantation</i> , 2017 , 31, e12868	3.8	22
135	Muscular exercise capacity and body fat predict VO(2peak) in heart transplant recipients. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 21-9	3.9	22
134	Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. <i>Circulation: Heart Failure</i> , 2013 , 6, 443-50	7.6	22
133	Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. <i>Circulation: Heart Failure</i> , 2018 , 11, e004050	7.6	22
132	Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 981-989	3.9	21
131	Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2017 , 4, 133-149	4.4	21
130	Limited Added Value of Circulating[Inflammatory Biomarkers in[Chronic Heart[Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 256-264	7.9	21
129	Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). <i>JACC: Heart Failure</i> , 2014 , 2, 35-40	7.9	21
128	Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. <i>PLoS ONE</i> , 2011 , 6, e18668	3.7	21
127	Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart[Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 405-419	15.1	21
126	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 923-931	3.9	20
125	Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013 , 168, 212-8	3.2	20
124	Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. <i>Scientific Reports</i> , 2017 , 7, 3490	4.9	20
123	The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure. <i>PLoS ONE</i> , 2012 , 7, e33038	3.7	20
122	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 31-6	6.4	19

121	Low fibre intake is associated with gut microbiota alterations in chronic heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 456-466	3.7	19	
120	Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. <i>Biomarkers</i> , 2017 , 22, 367-371	2.6	18	
119	The role of medical and psychosocial factors for unfavourable coronary risk factor control. <i>Scandinavian Cardiovascular Journal</i> , 2016 , 50, 1-8	2	18	
118	Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. <i>Atherosclerosis</i> , 2014 , 234, 352-9	3.1	18	
117	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , 2015 , 10, e0133970	3.7	17	
116	Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls. <i>Journal of Diabetes</i> , 2015 , 7, 779-90	3.8	17	
115	Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. <i>EBioMedicine</i> , 2020 , 60, 102985	8.8	17	
114	Altered Levels of Fatty Acids and Inflammatory and Metabolic Mediators in Epicardial Adipose Tissue in Patients With Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 916-23	3.3	16	
113	Increased Serum Levels of the Notch Ligand DLL1 are Associated with Diastolic Dysfunction, Reduced Exercise Capacity, and Adverse Outcome in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 218-23	3.3	15	
112	Importance of physical capacity and the effects of exercise in heart transplant recipients. <i>World Journal of Transplantation</i> , 2018 , 8, 1-12	2.3	15	
111	Contemporary Outcome in Patients With Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015 , 116, 952-9	3	14	
110	Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction. <i>EBioMedicine</i> , 2019 , 46, 264-273	8.8	14	
109	Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bfum Cardiovascular Diabetes (ABCD) study. <i>American Heart Journal</i> , 2014 , 168, 280-288.e2	4.9	13	
108	Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness. <i>Pregnancy Hypertension</i> , 2015 , 5, 325-9	2.6	13	
107	The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling. <i>PLoS ONE</i> , 2014 , 9, e112172	3.7	13	
106	Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. <i>Autoimmunity</i> , 2004 , 37, 489-93	3	13	
105	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-10n non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2018 , 271, 1-7	3.2	13	
104	The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2017 , 10, 401-410	03.3	12	

103	Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. <i>Heart</i> , 2016 , 102, 191	- ₹.1	12
102	Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients. <i>Open Heart</i> , 2017 , 4, e000635	3	12
101	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. <i>Transplantation</i> , 2020 , 104, 154-164	1.8	12
100	Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 823-8	3.3	12
99	Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention. <i>Scandinavian Journal of Public Health</i> , 2017 , 45, 269-276	3	11
98	Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens. <i>Clinical Transplantation</i> , 2017 , 31, e12927	3.8	11
97	The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 1097-1103	5.8	11
96	Morbidity outcomes after surgical aortic valve replacement. <i>Open Heart</i> , 2017 , 4, e000588	3	11
95	Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. <i>PLoS ONE</i> , 2015 , 10, e0139715	3.7	11
94	Immunomodulating therapy: new treatment modality in congestive heart failure. <i>Congestive Heart Failure</i> , 2003 , 9, 64-9		11
93	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 1111-24	2.5	11
92	Left Ventricular Contraction Pattern in Chronic Aortic Regurgitation and Preserved Ejection Fraction: Simultaneous Stress-Strain Analysis by Three-Dimensional Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 422-430.e2	5.8	10
91	Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia. <i>American Heart Journal</i> , 2016 , 172, 96-10.	0 \$ ·9	10
90	Unfavourable risk factor control after coronary events in routine clinical practice. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 40	2.3	10
89	Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, 153-9	3.3	10
88	6 min walk test is a strong independent predictor of death in outpatients with heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2904-2911	3.7	10
87	Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial. <i>Age and Ageing</i> , 2018 , 47, 42-47	3	9
86	The predictive value of coronary artery calcium detected by computed tomography in a prospective study on cardiac allograft vasculopathy in heart transplant patients. <i>Transplant International</i> , 2018 , 31, 82-91	3	9

(2015-2004)

85	Therapeutic potential of anticytokine therapy in congestive heart failure. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 169-77	4	9
84	Autonomic cardiovascular control changes in recent heart transplant recipients lead to physiological limitations in response to orthostatic challenge and isometric exercise. <i>European Journal of Applied Physiology</i> , 2019 , 119, 2225-2236	3.4	8
83	Rosuvastatin alters the genetic composition of the human gut microbiome. <i>Scientific Reports</i> , 2020 , 10, 5397	4.9	8
82	Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation. <i>International Journal of Cardiology</i> , 2016 , 223, 688-692	3.2	8
81	Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2019 , 274, 348-350	3.2	8
80	Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetesa cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2015 , 15, 147	2.3	8
79	The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial. <i>PLoS ONE</i> , 2014 , 9, e89732	3.7	8
78	Targeting the Inflammasome in Cardiovascular Disease <i>JACC Basic To Translational Science</i> , 2022 , 7, 84-98	8.7	8
77	Eliciting Patient Risk Willingness in Clinical Consultations as a Means of Improving Decision-Making of Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2016 , 5, e002828	6	8
76	Effect of Continuous Positive Airway Pressure on Arrhythmia in Atrial Fibrillation and Sleep Apnea: A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 573-582	10.2	8
75	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , 2020 , 34, e13984	3.8	7
74	Medical and sociodemographic factors predict persistent smoking after coronary events. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 241	2.3	7
73	Validity of standard gamble utilities in patients referred for aortic valve replacement. <i>Quality of Life Research</i> , 2016 , 25, 1703-12	3.7	7
72	Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. <i>Open Heart</i> , 2018 , 5, e000765	3	7
71	Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. <i>EBioMedicine</i> , 2021 , 70, 103511	8.8	7
70	Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). <i>Biomarkers</i> , 2017 , 22, 261-267	2.6	6
69	Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 94, 660-668	2.7	6
68	The Notch ligand Delta-like 1 is elevated and associated with mortality in patients with symptomatic aortic stenosis. <i>International Journal of Cardiology</i> , 2015 , 180, 18-20	3.2	6

67	Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 507-516	6.4	6
66	Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation. <i>Transplant Immunology</i> , 2016 , 38, 75-7	1.7	6
65	The role of statins in heart failure. Fundamental and Clinical Pharmacology, 2007, 21 Suppl 2, 35-40	3.1	6
64	High-intensity interval training and health-related quality of life in de novo heart transplant recipients - results from a randomized controlled trial. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 283	3	6
63	Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial. <i>Scandinavian Cardiovascular Journal</i> , 2018 , 52, 372-377	2	6
62	Connective tissue growth factor and bone morphogenetic protein 2 are induced following myocardial ischemia in mice and humans. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017 , 77, 321-331	2	5
61	Is the novel LDL-cholesterol goal . European Journal of Preventive Cardiology, 2020, 2047487320923187	3.9	5
60	Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease. <i>Heart</i> , 2014 , 100, 1793-8	5.1	5
59	Potential mechanisms of benefit with thalidomide in chronic heart failure. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 127-34	4	5
58	Clinical features and determinants of VO in heart transplant recipients. <i>World Journal of Transplantation</i> , 2018 , 8, 188-197	2.3	5
57	Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 359-367	5.8	5
56	The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up. <i>Psychosomatic Medicine</i> , 2019 , 81, 513-520	3.7	5
55	Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression. <i>American Journal of Transplantation</i> , 2019 , 19, 1050-1060	8.7	5
54	Optimal blood pressure control after coronary events: the challenge remains. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 823-830		4
53	Cognitive function among long-term survivors of heart transplantation. <i>Clinical Transplantation</i> , 2017 , 31, e13143	3.8	4
52	Statin-associated muscle symptoms in coronary patients: design of a randomized study. <i>Scandinavian Cardiovascular Journal</i> , 2019 , 53, 162-168	2	4
51	Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation. <i>Cardiovascular Diabetology</i> , 2019 , 18, 26	8.7	4
50	Results of comprehensive diagnostic work-up in Rediopathic Redilated cardiomy opathy. <i>Open Heart</i> , 2015 , 2, e000271	3	4

(2021-2016)

49	Patient characteristics and risk factors of participants and non-participants in the NOR-COR study. <i>Scandinavian Cardiovascular Journal</i> , 2016 , 50, 317-322	2	4
48	Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018 , 27, 650-656	1.8	4
47	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019 , 108, 133-141	6.1	4
46	Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages. <i>Atherosclerosis</i> , 2020 , 296, 74-82	3.1	4
45	Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1010-7	5.8	4
44	Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. <i>Transplantation</i> , 2019 , 103, 781-788	1.8	4
43	Long-term effects of high-intensity training vs moderate intensity training in heart transplant recipients: A 3-year follow-up study of the randomized-controlled HITTS study. <i>American Journal of Transplantation</i> , 2020 , 20, 3538-3549	8.7	3
42	Effect of high-intensity interval training in young heart transplant recipients: results from two randomized controlled trials. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2020 , 12, 35	2.4	3
41	Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 160	2.3	3
40	High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes. <i>Atherosclerosis</i> , 2019 , 282, 183-187	3.1	3
39	Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease. <i>Scandinavian Cardiovascular Journal</i> , 2012 , 46, 23-31	2	3
38	Circulating regulators of the wingless pathway in precapillary pulmonary hypertension. <i>Respirology</i> , 2021 , 26, 574-581	3.6	3
37	Outcomes in asymptomatic, severe aortic stenosis. <i>PLoS ONE</i> , 2021 , 16, e0249610	3.7	3
36	Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction. <i>Open Heart</i> , 2021 , 8,	3	3
35	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy. <i>Transplant International</i> , 2020 , 33, 517-528	3	2
34	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). <i>Clinical Transplantation</i> , 2017 , 31, e13038	3.8	2
33	Comparing manual and automatic scoring of sleep monitoring data from portable polygraphy. <i>Journal of Sleep Research</i> , 2021 , 30, e13036	5.8	2
32	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2021 , 111, 440	6.1	2

31	Elevated levels of the secreted wingless agonist R-spondin 3 in preeclamptic pregnancies. <i>Journal of Hypertension</i> , 2020 , 38, 1347-1354	1.9	2
30	Early Signs of Sinoatrial Reinnervation in the Transplanted Heart. <i>Transplantation</i> , 2021 , 105, 2086-2096	51.8	2
29	Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation. <i>European Heart Journal</i> , 2021 ,	9.5	2
28	Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: observations from the Akershus Cardiac Examination (ACE) 1 Study. <i>Cytokine</i> , 2015 , 73, 122-7	4	1
27	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. <i>ESC Heart Failure</i> , 2020 , 7, 567-576	3.7	1
26	Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018 , 5, 1052-1059	3.7	1
25	Sleep-disordered Breathing in Heart Failure - Current State of the Art. <i>Cardiac Failure Review</i> , 2015 , 1, 16-24	4.2	1
24	Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study. <i>Open Heart</i> , 2020 , 7,	3	1
23	Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension. <i>Scientific Reports</i> , 2020 , 10, 18540	4.9	1
22	Prevalence of iron deficiency in heart transplant recipients. Clinical Transplantation, 2021, 35, e14346	3.8	1
21	Functional evidence of low-pressure cardiopulmonary baroreceptor reinnervation 1 year after heart transplantation. <i>European Journal of Applied Physiology</i> , 2021 , 121, 915-927	3.4	1
20	Machine Learning for Sleep Apnea Detection with Unattended Sleep Monitoring at Home. <i>ACM Transactions on Computing for Healthcare</i> , 2021 , 2, 1-25	2.6	1
19	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , 2021 , 9, 653-663	7.9	1
18	Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis. Journal of Heart Valve Disease, 2017 , 26, 413-422		1
17	The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure <i>Frontiers in Immunology</i> , 2021 , 12, 800978	8.4	1
16	Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial <i>EBioMedicine</i> , 2022 , 80, 104013	8.8	1
15	EBlocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. <i>Biomedicine Hub</i> , 2020 , 5, 9-18	1.3	0
14	Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121009:	233	O

LIST OF PUBLICATIONS

13	Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2425-2435	15.1	O
12	YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2020 , 13, e006643	7.6	O
11	Symptoms of anxiety after heart transplantation and their association with mortality: A secondary analysis. <i>Clinical Transplantation</i> , 2021 , 35, e14323	3.8	О
10	Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis. <i>Open Heart</i> , 2018 , 5, e000901	3	O
9	Comparison of simplified and comprehensive methods for assessing the index of microvascular resistance in heart transplant recipients. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 28.	3- 9 0 ⁷	
8	Newer Immunosuppression and Strategies on the Horizon in Heart Transplantation. <i>Current Transplantation Reports</i> , 2017 , 4, 226-237	1.5	
7	A randomized clinical study using optical coherence tomography to evaluate the short-term effects of high-intensity interval training on cardiac allograft vasculopathy: a HITTS substudy. <i>Clinical Transplantation</i> , 2021 , e14488	3.8	
6	Response to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819	5	
5	Response by Nytrën et al to Letter Regarding Article, "Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia". <i>Circulation</i> , 2019 , 140, e735-e736	16.7	
4	Authorß response to: letter to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819	5	
3	The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease. <i>Atherosclerosis</i> , 2021 , 336, 23-29	3.1	
2	Reply: Safety of intravenous iron in heart transplant patients: Comment to paper by Brautaset Englund et al. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1247-1248	5.8	
1	Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo <i>Clinical Transplantation</i> , 2022 , e14695	3.8	